Volker Heinemann

Computed Tomography Image-Based Deep Survival Regression for Metastatic Colorectal Cancer Using a Non-proportional Hazards Model

Horst-Michael Groß, Alexander Mühlberg, Alexander Katzmann, 2019, PRIME@MICCAI.

Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.

Sabine Tejpar, Volker Heinemann, Frank Beier, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gemcitabine: Progress in the Treatment of Pancreatic Cancer

Volker Heinemann, V. Heinemann, 2000, Oncology.

Nomogram including pretherapeutic parameters for prediction of survival after SIRT of hepatic metastases from colorectal cancer

Marcus Hacker, Peter Bartenstein, Tobias F. Jakobs, 2013, European Radiology.

Addressing the challenges of pancreatic cancer: future directions for improving outcomes.

Manuel Hidalgo, Volker Heinemann, R. Labianca, 2015, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

Percutaneous radiofrequency ablation (RFA) or robotic radiosurgery (RRS) for salvage treatment of colorectal liver metastases

Ralf-Thorsten Hoffmann, Alexander Muacevic, Christoph G Trumm, 2013, Acta oncologica.

Predicting Lesion Growth and Patient Survival in Colorectal Cancer Patients using Deep Neural Networks

Horst-Michael Gross, Alexander Katzmann, Julian Walter Holch, 2018 .

Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database.

Daniel J Sargent, Christophe Tournigand, Eduardo Diaz-Rubio, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3).

Michael Scholz, Volker Heinemann, W. Scheithauer, 2013 .

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.

Hartmut Link, Michael Scholz, Thomas Kirchner, 2014, The Lancet. Oncology.